Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 53 Carcinoma, Non-Small-Cell Lung 50 Carcinoma, Renal Cell 32 Neoplasms 29 Neoplasm Metastasis 24 Colorectal Neoplasms 21 Carcinoma, Hepatocellular 21 Squamous Cell Carcinoma of Head and Neck 18 Stomach Neoplasms 16 Triple Negative Breast Neoplasms 15 Ovarian Neoplasms 14 Small Cell Lung Carcinoma 11 Pancreatic Neoplasms 11 Lung Neoplasms 11 Hodgkin Disease 11 Carcinoma, Transitional Cell 10 Advanced Cancer 9 Sarcoma 8 Recurrence 8 Head and Neck Neoplasms 8 Solid Tumor 7 Prostatic Neoplasms 7 Lymphoma, Non-Hodgkin 7 Endometrial Neoplasms 7 Uterine Cervical Neoplasms 6 Urinary Bladder Neoplasms 6 Carcinoma, Merkel Cell 6 Breast Neoplasms 6 Mesothelioma 5 Glioblastoma 5

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 durvalumab 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Cancer × Nivolumab × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡